Search

everythinglearnresearchcommunity

for

Search:↓

20(S)-Protopanaxadiol-aglycone may help prevent and treat prostate cancer by reducing androgen receptor activity.

Enobosarm may effectively treat androgen receptor-positive breast cancer with fewer side effects.

Sacituzumab tirumotecan shows promise in treating breast cancer with manageable side effects.

INTASYL is a promising, adaptable RNAi technology for treating skin cancers.

Vepdegestrant may become the first FDA-approved PROTAC degrader, marking a new era in drug development.

The drug IPI-926 is safe at 160 mg daily and may help treat certain tumors, especially basal cell carcinoma.

Some existing drugs and natural products might work against COVID-19 by targeting the virus's main protease.

New cancer drugs can cause skin side effects like rashes, dry skin, hair changes, and nail problems.

Tadalafil and Finasteride may help treat aggressive melanoma.

The treatment was effective for advanced non-Hodgkin's lymphomas.

Inhibiting mTORC2 can reduce DNA repair and increase cancer cell death, suggesting potential for targeted brain cancer treatments.

Dermatologists are crucial for managing skin side effects in metastatic melanoma patients using vemurafenib and ipilimumab.

SARMs may be an effective treatment for a certain type of breast cancer by blocking cancer growth and spread.

Over 30 potential cancer prevention treatments are being tested, with some showing promise in early research.

The document concludes that Catalyst software is effective for drug design, identifying potent compounds for various medical conditions.

Afatinib, neratinib, and zanubrutinib could be effective against KRASG12C-mutant tumors.

New treatments for advanced skin cancer are improving patient outcomes, but drug resistance and finding the right treatment combinations are still big challenges.

Most patients experienced mild to moderate skin problems during a trial for a desmoid tumor treatment.

Pemigatinib may be effective for treating ZMYM2::FGFR1 fusion-positive leukemia.

Trodelvy™ helped some patients with advanced breast cancer, but had side effects.

CEP135 may predict cancer outcomes, and targeting PLK1 could help treat certain sarcomas.

PEVIII is a promising treatment for Pseudomonas aeruginosa keratitis.

Pantethine may boost the immune system's ability to fight sarcoma.

Provenge extends prostate cancer survival by about 4 months.

CDK4/6 inhibitors have improved treatment outcomes for certain advanced breast cancer patients.

The new delivery system improved raloxifene's skin absorption and effectiveness against cancer cells.

Topical PROTACs show promise for treating skin conditions but need better stability and delivery methods.

Liarozole may be more effective than cyproterone acetate for treating advanced prostate cancer, with better PSA response and survival rates, while maintaining quality of life.

Ponatinib can cause a rare skin reaction that resolves with topical treatment and temporary drug discontinuation.

PX-12 may help treat psoriasis by blocking inflammation and cell death.